Q3 2026
Released Feb 6, 2026, before the open
10-Q filed Feb 6, 2026, 37 days after period end · 0001764013-26-000011
Q3 2026 · 10-Q
Revenue—
Net Income-$110.64M-$110.64M N/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.61-$0.61 N/M vs Q3 2025N/M vs Q2 2026
Operating Cash Flowderived-$92,325,000N/M
Free Cash Flowderived-$92,325,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$110.64M | -$111.12M | -$51.42M | -$63.23M |
| EPS Diluted | -$0.61 | -$0.76 | -$0.36 | -$0.49 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR